Geron Co. (NASDAQ:GERN) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. grew its position in Geron Co. (NASDAQ:GERN) by 23.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,802 shares of the biopharmaceutical company’s stock after buying an additional 4,094 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Geron were worth $100,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in GERN. National Bank of Canada FI grew its position in shares of Geron by 1,200.0% in the second quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 6,000 shares during the last quarter. Crewe Advisors LLC lifted its position in Geron by 870.0% during the 1st quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 8,700 shares in the last quarter. Kingsview Wealth Management LLC bought a new stake in shares of Geron during the first quarter valued at approximately $34,000. American Trust bought a new position in Geron in the 1st quarter valued at $38,000. Finally, CIBC Asset Management Inc increased its position in Geron by 32.7% in the second quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 3,805 shares during the period. 73.71% of the stock is owned by hedge funds and other institutional investors.

Geron Stock Up 3.4 %

NASDAQ GERN opened at $4.25 on Tuesday. Geron Co. has a fifty-two week low of $1.64 and a fifty-two week high of $5.34. The business has a fifty day moving average price of $4.35 and a two-hundred day moving average price of $4.29. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.61 and a quick ratio of 3.60. The stock has a market capitalization of $2.56 billion, a PE ratio of -11.69 and a beta of 0.52.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.10). The company had revenue of $0.88 million for the quarter, compared to the consensus estimate of $0.34 million. Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. The firm’s quarterly revenue was up 2941.4% compared to the same quarter last year. During the same period last year, the company posted ($0.09) EPS. Equities analysts expect that Geron Co. will post -0.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on GERN. StockNews.com raised shares of Geron to a “sell” rating in a report on Monday, August 5th. Leerink Partners assumed coverage on shares of Geron in a research note on Monday, September 9th. They set an “outperform” rating and a $7.00 target price for the company. Wedbush reissued an “outperform” rating and issued a $8.00 price target on shares of Geron in a report on Thursday, August 8th. Leerink Partnrs upgraded Geron to a “strong-buy” rating in a research note on Monday, September 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of Geron in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $6.94.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.